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Abstract
Background—Cardiovascular disease (CVD) is of increasing concern among breast cancer 
survivors. However the burden of this comorbidity in this group relative to the general population, 
and its temporal pattern, remains unknown.
Methods—We compared deaths due to CVD in a population-based sample of 1,413 women with 
incident breast cancer diagnosed in 1996-1997, and 1,411 age-matched women without breast 
cancer. Date and cause of death through December 31, 2009 were assessed through the National 
Death Index and covariate data was gathered through structured interviews and medical record 
abstraction. Hazard ratios and 95% confidence intervals (CI) were calculated using Cox regression 
for overall mortality (HR) and CVD-specific death (cause-specific HR). Subdistribution hazard 
ratios (sHR) for CVD death were estimated from the Fine-Gray model.
Results—Risk of death was greater among breast cancer survivors compared to women without 
breast cancer [HR: 1.8 (1.5, 2.1)]. An increase in CVD-related death among breast cancer 
survivors was evident only 7 years after diagnosis [years 0-7, cause-specific HR: 0.80 (0.53, 1.2), 
subdistribution HR: 0.59 (0.40, 0.87)]; years 7+, cause-specific HR: 1.8 (1.3, 2.5), subdistribution 
HR: 1.9 (1.4, 2.7); p-interaction: 0.001]. An increase in CVD-related mortality was observed 
among breast cancer survivors receiving chemotherapy.
Conclusions—Breast cancer survivors are at greater risk for CVD-related mortality compared to 
women without breast cancer and this increase in risk is manifest approximately 7 years after 
diagnosis. Efforts should be made to identify risk factors and interventions that can be employed 
during this brief window to reduce the excess burden of CVD in this vulnerable population.
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Introduction
Breast cancer mortality among American women has decreased by more than 2% per year in 
the last decade1, with nearly 90% of breast cancer patients currently surviving 5 years past 
their date of diagnosis.2 In the United States there are nearly 3 million female breast cancer 
survivors3 many of whom die from conditions unrelated to their malignancy.4,5 This trend 
becomes more pronounced as age at diagnosis increases6 and among those with early stage 
disease.4,6
Cardiovascular disease (CVD) is an important public health issue; among the general U.S. 
population it represents the leading cause of death among both men and women7 and is an 
issue of growing concern among cancer survivors.8-11 For breast cancer survivors 
specifically, CVD represents the greatest single non-cancer cause of death, accounting for 
approximately 35% of non-breast cancer mortality for survivors 50 years of age and older.6 
However, our current understanding of the etiology of CVD among breast cancer survivors 
is limited.10,12 Previous studies have examined risk factors for CVD-related mortality within 
cohorts of cancer survivors only, mostly focusing on breast cancer treatment.10,13 Although 
an increased risk of CVD has been documented in clinical studies, there have been few 
reports of the magnitude of this comorbidity in population-based cohorts of breast cancer 
survivors. Furthermore, the extent to which breast cancer survivors experience CVD related 
outcomes relative to women without breast cancer, and the time when any excess risk of 
CVD becomes manifest, has not been formally evaluated previously. This ambiguity limits 
the ability for clinicians to identify and provide accurate recommendations for CVD risk 
reduction strategies specific to breast cancer survivors, particularly with regard to the timing 
of the interventions.
The objective of this study was to estimate the relative burden of death due to CVD among a 
population-based sample of breast cancer survivors compared to an age-matched sample of 
women without breast cancer. We also explored whether rates of CVD death varied over 
time or according to cancer-related treatments.
Methods
This follow-up study uses resources from the population-based Long Island Breast Cancer 
Study Project (LIBCSP),14 which was approved by the Institutional Review Board of 
participating institutions.
Study Population
Women with breast cancer were English-speaking adults diagnosed with a first primary in 
situ or invasive breast cancer between August 1, 1996-July 31, 1997, and residents of 
Nassau or Suffolk counties, NY. Potentially eligible women with breast cancer were 
identified through all hospitals in the study catchment area, and patients’ physicians were 
contacted to confirm the diagnosis and obtain permission to contact the women. Women 
without breast cancer were residents of the same two counties in NY, frequency matched to 
the expected distribution of survivors in 5-year age groups, and identified using random 
digit dialing for those under 65 years of age, and from Health Care Finance Rosters for those 
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age 65 or over. Baseline interview respondents included 1,508 women with (82.1% of 
eligible cases) and 1,556 without breast cancer (62.7% of eligible controls). Women ranged 
from 20 to 98 years of age at baseline, and 94% were white and 4% were African American. 
At baseline, 1,414 breast cancer survivors agreed to be re-contacted, and 1,033 ultimately 
participated in the follow-up interview.
Outcome Assessment
The National Death Index,15 was used to establish vital status for all LIBCSP participants 
through 2009. We considered death from any cause (n=712; 268 women without breast 
cancer and 444 breast cancer survivors), as well as death from CVD (n=300; 129 and 171, 
respectively) if any of the following cardiovascular disease-related International 
Classification of Disease codes were listed as the primary cause of death: 394.9, 402.9, 410, 
414.0, 427.5, I10, I11.9, I21.9, I25.1, I25.4 and I46.9. These codes were selected to include 
common cardiovascular disease outcomes, including myocardial infarction, cardiac arrest, 
hypertensive heart disease, coronary artery aneurysm and dissection. Women without a 
death record match in the NDI database were deemed alive as of December 31, 2009. 
Follow-up time ranged from 0.2 to 13.5 years.
Covariates
After signed informed consent was obtained, all participants completed the in-person 
baseline interview, which occurred within approximately 3 months of diagnosis for women 
with breast cancer. The baseline interview included assessment of history of comorbidities, 
menopausal status, education, income, first course of treatment for the first primary breast 
cancer diagnosis, and other factors. Only women with breast cancer were asked to complete 
the telephone follow-up interview, which occurred approximately 5 years later, to obtain 
more detailed information on full course of treatment for the first primary breast cancer.
Medical records were reviewed for information on tumor characteristics and treatment for 
1,402 women with breast cancer who signed a medical record release form at baseline, and, 
again, for 598 women with breast cancer who signed a medical record release at the follow-
up interview. Treatment data from the medical record agreed strongly with the data from the 
follow-up questionnaire16 (kappa coefficients: radiation therapy κ=0.97, chemotherapy 
κ=0.96 and hormone therapy κ=0.92), and thus the self-reported data are used in these 
analyses. Data on tumor size was collected from the New York State Cancer Registry.
Statistical Analysis
All statistical analyses were conducted using Stata 13 (College Station, TX). For overall 
mortality, Kaplan-Meier failure curves were calculated and Cox proportional hazards 
regression17 was used to estimate adjusted hazard ratios (HR) and 95% confidence intervals 
(CI). For CVD mortality we conducted a competing risks analysis18-20 because other causes 
of death (e.g. breast cancer) may remove women from the risk set before the event of 
interest (CVD mortality) is observed. For CVD-related death we estimated the competing 
risks analog to the Kaplan-Meier failure function, the cumulative incidence function.21 For 
the competing risks analysis we estimated two measures of association: the cause-specific 
hazard ratio and the subdistribution hazard ratio.19 The cause-specific hazard ratio 
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represents the rate at which women with breast cancer experience CVD-related deaths 
relative to women without breast cancer among those still alive;22,23 this was estimated from 
a Cox model with all non-CVD causes of death treated as censored. The subdistribution 
hazard ratios indicate the relative difference in the cumulative incidence of CVD deaths 
between women with and without breast cancer,18,19 and were estimated using the Fine-
Gray model.22 The subdistribution hazard ratio accounts for the influence of other causes of 
death (e.g. breast cancer) that would render subjects incapable of experiencing the death of 
interest (CVD), and therefore reflects the relative risk of experiencing a CVD-related 
death.22,23
Confounders included variables that may affect both breast cancer incidence and 
cardiovascular disease mortality: age (at reference date=date of diagnosis for women with 
breast cancer or date of identification for women without breast cancer; restricted cubic 
spline with 5 knots at equally spaced percentiles), menopausal status (pre-/post-
menopausal), previous use of hormone replacement therapy (HRT, yes/no), cigarette 
smoking history (never, passive exposure only, active smoker only, both active smoker and 
passive exposure), average lifetime alcohol intake (non-drinkers, <15 g/day, 15-30 g/day, 30 
or more g/day), body mass index (BMI, kg/m2) the year before reference date and self-
reported history of the following comorbidities at reference date: diabetes, dyslipidemia, 
myocardial infarction, hypertension, or stroke. All confounders were ascertained relative to 
the study participant’s reference date. We additionally considered adjustment for additional 
factors that could be related to access to care, health care utilization and health behavior 
(income and education) and cardiovascular disease risk (cholesterol-lowering medications 
and aspirin use), but adjustment for these factors did not materially change the estimates and 
thus we did not include them in the final models. The proportional hazards assumption was 
assessed using a Wald test for the interaction between follow-up time and each covariate. 
Violations of this assumption were noted for history of myocardial infarction and 
hypertension for overall mortality, and for history of diabetes for CVD mortality, therefore 
the final respective models included interactions between these terms and follow-up time. 
Breast cancer status also violated this assumption in all models, and so the overall 
association is interpreted as an average effect over the entire follow-up period;23 we 
additionally report this association separated by duration of follow-up, described below.
We evaluated the potential for the association with breast cancer status to vary over time by 
exploring interactions with follow-up time categorized as before and after 6 years of follow-
up (e.g. follow-up time ≤ 6 years vs. > 6 years) for overall mortality, and 7 years for CVD 
mortality, determined to be the most meaningful cutpoints based on empirical results and 
visual inspection of Kaplan-Meier failure curves and cumulative incidence function plots. 
Significance in this interaction was determined at the 5% level. We additionally explored 
heterogeneity of the association among breast cancer survivors by classifying them 
according to treatment (chemotherapy, hormone therapy, radiation therapy). Small numbers 
for these subgroup analyses precluded categorization of breast cancer survivors into more 
detailed treatment types or combinations.
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Final Analytic Sample Size
Small amounts of missing data were noted for baseline menopausal status (30 cases/63 
controls), history of HRT (4 cases/1 control), smoking (37 cases/42 controls), BMI (17 
cases/28 controls), or any CVD-related comorbidity (9 cases/13 controls) yielding a sample 
of 1,413 women with, and 1,411 women without, breast cancer for the primary analyses.
Results
At the reference date the mean age of women in our sample was 57 years for women without 
breast cancer and 59 years for women with breast cancer. In our population-based sample of 
1,413 women diagnosed with a first primary breast cancer in 1996-1997 the number of 
deaths through 2009 was higher for all-cause and CVD-related mortality (415 and 133, 
respectively) than among the 1,411 age-matched population-based women without breast 
cancer (242 and 105, respectively) (Table 1). When considering the six pre-existing CVD-
related risk factors (history of myocardial infarction, history of stroke, pre-existing diabetes, 
hypertension or high cholesterol, or BMI>=30 kg/m2), we noted that the average number of 
risk factors was slightly higher among women with breast cancer (mean: 1.03) than among 
women without breast cancer (0.97).
As shown in Figure 1, risk of death from all causes was greater among breast cancer 
survivors compared to the population-based sample without breast cancer [adjusted HR 
(95% CI): 1.8 (1.5, 2.1)]. Breast cancer was also associated with greater rate of CVD-related 
death across the entire follow-up [adjusted cause-specific HR: 1.3 (1.0, 1.7); subdistribution 
HR: 1.2 (0.89, 1.5)].
CVD-related mortality among the breast cancer survivors appeared to increase sharply after 
approximately year 5. Analyses that considered heterogeneity of these relationships over the 
follow-up showed a significant difference in the association between mortality and breast 
cancer status over time (Table 2). As expected, within the first 6 years the overall mortality 
rate was much greater among breast cancer survivors than women without breast cancer 
[within years 0-6, HR: 2.2 (1.7, 2.8); after year 6, HR: 1.5 (1.3, 1.9), p-interaction: 0.04], 
largely driven by the greater number of breast cancer-related deaths among survivors in the 
years immediately following diagnosis. However, the rate of CVD death was greater among 
longer-term breast cancer survivors compared to the women without breast cancer after 7 
years of follow-up [csHR: 1.8 (1.3, 2.5)]. In contrast, there was a trend towards an inverse 
association of breast cancer status with CVD-related death within the first 7 years [cause-
specific HR: 0.80 (0.53, 1.2), p-interaction: 0.004]. After year 7, breast cancer survivors had 
nearly twice the risk of CVD mortality compared to those without breast cancer [sHR: 1.9 
(1.4, 2.7)], while the risk of CVD death was lower among breast cancer survivors in the 
early years [years 0-7, subdistribution HR: 0.59 (0.40, 0.87), p-interaction <0.001]. This 
reduction in incident CVD mortality among survivors in the short term most likely reflects 
the influence of the major competing risk in this group (breast cancer-related death).
The CVD-specific mortality rate was elevated among those who received chemotherapy 
[cause-specific HR: 1.7 (1.1, 2.6)] but not those not receiving chemotherapy [cause-specific 
HR: 1.1 (0.82, 1.6)] (Table 3). Similar increases were observed regardless of receipt of 
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hormone therapy, while a more pronounced, but non-significant increase was seen among 
those not receiving radiation therapy [without radiation therapy cause-specific HR: 1.5 (1.0, 
2.2); with radiation therapy cause-specific HR: 1.2 (0.82, 1.7)]. Associations with the 
cumulative incidence of CVD death (sHRs) followed similar patterns, but were attenuated. 
Given that adjuvant chemotherapy is associated with early menopause, which may impact 
CVD risk, we conducted an exploratory analysis where we examined the relationship with 
chemotherapy treatment among women who were pre-menopausal at diagnosis (n=466 
women with breast cancer and 485 women without) and found more pronounced 
associations with chemotherapy in this subgroup than we observed in the overall population 
[cause-specific HR: 2.8 (1.3, 6.3), sHR: 2.5 (1.1, 5.7) among women receiving 
chemotherapy vs. women without breast cancer; cause-specific HR: 1.4 (0.43, 
4.3),subdistribution HR: 1.4 (0.43, 4.2) among women not receiving chemotherapy vs. 
women without breast cancer] (data not in table).
Discussion
We are the first, to our knowledge, to determine that death due to CVD is higher among a 
population-based cohort of breast cancer survivors than a comparable group of women 
without breast cancer. We were also able to identify at which point after diagnosis—
approximately year 7—CVD becomes a disproportionate cause of death for cancer 
survivors. The increase in CVD-related mortality among breast cancer survivors, compared 
to other women, appeared to be strongest among survivors who received chemotherapy for 
their first primary breast cancer. Our finding that breast cancer survivors are at greater risk 
for CVD than women without breast cancer has important clinical implications for these 
women who are already older at diagnosis, and the long-term survivors who continue to age.
The most noteworthy finding of our study is that the increased risk of CVD-related death 
among breast cancer survivors does not become apparent until several years after diagnosis. 
The near-null cause-specific HR for CVD mortality observed within the first 7 years reflects 
the fact that near diagnosis the rate of CVD mortality is similar between breast cancer 
survivors and women without breast cancer, however the significant inverse subdistribution 
HR suggests that the cumulative incidence of CVD-related death is lower among breast 
cancer survivors during this time since breast cancer survivors are more likely to experience 
the competing risk of breast cancer-related death. However, this dynamic appears to change 
around year 7, when not only does the influence of the competing risk decrease, but the 
association of breast cancer diagnosis with rate of CVD death increases sharply. These two 
factors combine to yield a nearly twofold increase in the incidence of CVD for these long-
term survivors (shown by the subdistribution HR in years 7+). The current paradigm that 
suggests survivorship 5 years after diagnosis is a meaningful threshold for cancer 
survivors24 does not account for the substantial increase in risk of non-cancer related death 
that occurs after this point. Instead, it over-emphasizes improvements in short-term survival 
attributable to improvements in treatment, while ignoring the sizeable late effects of such 
treatment on risk of potentially fatal comorbidities, in particular cardiovascular disease.
Several potential mechanisms could play a role in these associations. Cancer survivors have 
been reported to have a higher prevalence of CVD risk factors compared to the general 
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population,25 although this difference was not pronounced in our cohort when we compared 
the average number of risk factors between women in these two groups. Additionally, the 
cardiotoxic effects of breast cancer treatments, specifically radiotherapy and chemotherapy, 
are well documented.10,13,26 Anthracycline-related cardiotoxicity is especially 
established,26,27 however this agent is predominantly related to congestive heart failure and 
cardiomyopathy,26,27 which were not included in our definition of CVD-related death. 
Therefore, the observed increase in CVD-related deaths among women receiving 
chemotherapy could be attributed to a number of other agents with effects that act on the 
cardiovascular system.26 In addition to any direct effects of chemotherapy on CVD risk, 
there may be indirect mechanisms linked with early menopause,28 which is associated with 
unfavorable changes in lipid levels29 and hemostasis factors30 that may increase risk of 
cardiovascular events.31 This is consistent with our observation of a more pronounced 
association for chemotherapy treatment among pre-menopausal women. Our overall finding 
of an increased risk of CVD-related death among breast cancer patients who underwent 
chemotherapy is consistent with these previous studies, yet we are the first to quantify the 
magnitude of this increase compared to women without breast cancer. We did note a modest 
decrease in the rate of CVD-related death among women with breast cancer in the first 
several years after diagnosis, which could be consistent with a previously noted reduction in 
death due to myocardial infarction associated with tamoxifen.32 However, a limited number 
of events in the years shortly after diagnosis limited our ability to examine treatment-by-
time interactions in this analysis.
Although our finding of no increase in CVD mortality among those receiving radiation 
therapy was in agreement with some previous studies,33,34 this result lies in contrast to 
others.9,35-39 Radiation therapy, in particular to the left side of the chest wall, may increase 
CVD risk through injury to cardiac muscle or the surrounding vasculature.40 However, 
several recent studies have failed to observe a difference in cardiac events between women 
receiving radiation therapy for left- vs. right-sided tumors.34,42,43 A potential explanation 
for these recent null findings, including ours, is that current radiotherapy techniques are 
more targeted and less cardiotoxic than older regimens.41,42 It is also possible that the 
severity or form of radiation-induced CVD is less fatal than chemotherapy-induced disease, 
as our outcome was mortality rather than incident disease. Alternatively, radiation-induced 
CVD could take longer to manifest than we have available follow-up, as studies have found 
an increase in risk of morbidity or mortality more than 15 years36 to 20 years37,39 after 
treatment, a time period several years past what we had available. Other reports have found 
a synergistic effect between radiotherapy and other systemic therapies13 that we did not 
have the study power to examine here.
A major strength of our study includes the innovative focus on a population-based sample of 
women with and without breast cancer. We are the first, to our knowledge, to compare risk 
for non-cancer mortality between a cohort of breast cancer survivors and a sample of women 
without breast cancer from the same source population. This study design offers a unique 
opportunity to identify differences in the risk of health outcomes between breast cancer 
survivors and a comparable group of women without breast cancer. Nearly all of the 
previous epidemiologic studies of cancer survivors have been limited to identification of risk 
factors among survivors alone. Our novel design allows us to identify unique patterns of risk 
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in this subgroup, in particular the time at which risk between these two groups diverges. Our 
findings suggest that breast cancer survivors should be closely monitored for development 
of cardiovascular abnormalities and CVD risk factors beginning in the years immediately 
following diagnosis and treatment. Importantly, our population-based design strengthens the 
interpretation of our findings—since the study participants with and without breast cancer 
were both representative of the same source population from which they are drawn.
Although this study has noteworthy strengths, our conclusions must be interpreted in light of 
potential limitations. The women from this cohort are predominantly white, and these 
findings may not be generalizable to other racial and ethnic groups. Although we controlled 
for pre-existing comorbid conditions that may be related to CVD-mortality (and potentially 
breast cancer treatment choices), there is the potential for residual confounding by the 
degree to which the comorbid conditions are controlled or confounding by indication for 
analysis of treatment-specific effects. Data on cause of death was determined through the 
National Death Index (NDI), a reliable source for determination of all-cause mortality.15 
The NDI uses death certificate information to establish cause of death, which is a potential 
source of misclassification. However, our conclusions that the rate of overall mortality 
between those with and without breast cancer tended to converge over time, while the CVD-
related mortality rate was initially identical, then diverged, suggests that classification of 
death was accurate, or at least that any misclassification would be nondifferential. Such 
misclassifiation would result in either bias toward the null, or in certain circumstances, no 
bias.44 Another potential concern is our use of self-reported data for pre-existing CVD-
related comorbidities. Yet self-reported comorbidities such as those considered here have 
been demonstrated to be associated with mortality in similar cohorts.45,46 Additionally, 
given the size of our study, we were only able to evaluate treatment modalities broadly and 
not by specific agents. Subsequent studies would be improved by a larger sample size, 
which would facilitate more detailed analyses, such as death from specific CVD-related 
conditions, or due to specific chemotherapy agents or combinations of treatments.
Our results show that years after diagnosis and treatment long-term breast cancer survivors 
are at increased risk of death due to cardiovascular disease compared to women from the 
general population. In future, larger studies are needed to confirm our findings and identify 
the forms of CVD that are most common in this group, as well as including incident CVD as 
well as CVD-related mortality. Identification of potential mechanisms through which the 
breast cancer survivorship experience influences CVD etiology will help identify potential 
targets for intervention in this high-risk population.
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Figure 1. 
Unadjusted Kaplan-Meier failure curves and adjusted hazard ratios (HR) for overall 
mortality (first panel) and cumulative incidence function, cause-specific HR (csHR) and 
subdistribution HR (sHR) for CVD-related mortality (second panel) among a population-
based sample of breast cancer survivors and age-matched women without breast cancer. The 
Long Island Breast Cancer Study, 1996-2009.
*HRs adjusted for age at reference date (age at diagnosis for breast cancer survivors and 
date of identification for women without breast cancer), menopausal status, previous use of 
hormone replacement therapy, smoking history, average lifetime alcohol intake, body mass 
index the year before reference date, income, education, and history of the following 
cardiovascular disease risk factors: diabetes, myocardial infarction, hypertension, 
dyslipidemia or stroke. Model for overall mortality included interaction between follow-up 
time and history of hypertension and myocardial infarction and models for CVD mortality 
included interaction between follow-up time and history of diabetes.
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Table 1
Baseline characteristics, and vital status as of December 31, 2009, among a population-based sample of 1,413 
breast cancer survivors and 1,411 women without breast cancer frequency matched by age. Long Island Breast 
Cancer Study Project, 1996-2009.
Women without
Breast Cancer
(n=1,411)
Breast Cancer
Survivors
(n=1,413)
Deaths from any cause 242 415
Deaths from CVDa 105 133
Deaths from Breast Cancera 2 135
Menopausal status
Premenopausal, No. (%) 485 (34) 466 (33)
Postmenopausal, No. (%) 926 (66) 947 (67)
Ever used hormone
replacement therapy
No 1,073 (76) 1,033 (73)
Yes 338 (24) 408 (27)
Smoking
Never 177 (13) 161 (11)
Passive exposure only 465 (33) 464 (33)
Ever active smoker only 132 (9.4) 133 (9.4)
Both active and passive 637 (45) 655 (46)
Alcohol intake,
Lifetime average g/day
Non-drinker 551 (39) 550 (39)
0-15 672 (48) 651 (46)
15-30 107 (7.6) 142 (10)
>=30 81 (5.7) 70 (4.9)
BMIb (kg/m2)
in year before reference dateb
<18.5 31 (2.2) 25 (1.8)
18.5-24.9 662 (47) 629 (44)
25.0-29.9 415 (29) 450 (32)
≥30.0 303 (22) 309 (22)
Hypertension
No 946 (67) 925 (65)
Yes 465 (33) 488 (34)
Diabetes
No 1,313 (93) 1,285 (91)
Yes 98 (6.9) 128 (9.1)
High Cholesterol
No 980 (69) 988 (70)
Yes 431 (30) 425 (30)
Myocardial Infarction
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Women without
Breast Cancer
(n=1,411)
Breast Cancer
Survivors
(n=1,413)
No 1,367 (97) 1,356 (96)
Yes 44 (3.1) 57 (4.0)
Stroke
No 1,387 (98) 1,372 (97)
Yes 24 (1.7) 41 (2.9)
Chemotherapy
No N/A 561 (58)
Yes N/A 400 (42)
Radiation Therapy
No N/A 375 (39)
Yes N/A 590 (61)
Hormone Therapy
No N/A 369 (39)
Yes N/A 580 (61)
Tumor size
<2cm N/A 781 (76)
>=2cm N/A 248 (24)
Missing N/A 479
aCVD: cardiovascular disease. According to primary cause of death field from National Death Index data.
b
BMI: body mass index.
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Table 2
Overall and CVD mortality among a population-based sample of breast cancer survivors and women without 
breast cancer stratified by time since the beginning of follow-up. The Long Island Breast Cancer Study 
Project, 1996-2009.
Overall Mortality
HRa (95% CI)
Time since beginning
of follow-up
Women without
Breast Cancer
(235 deaths)
Breast Cancer
Survivors
(407 deaths) pb
0-6 years 1.0 2.2 (1.7, 2.8) 0.04
>6 years 1.0 1.5 (1.3, 1.9)
CVD Mortality
Time since beginning
of follow-up
Women without
Breast Cancer
(114 deaths)
Breast Cancer
Survivors
(155 deaths)
Cause-specific HRa,c (95% CI) pb
0-7 years 1.0 0.80 (0.53, 1.2) 0.004
>7 years 1.0 1.8 (1.3, 2.5)
Subdistribution HRa,d (95% CI) pb
0-7 years 1.0 0.59 (0.40, 0.87) <0.001
>7 years 1.0 1.9 (1.4, 2.7)
a
Models adjusted for age at reference date (date of diagnosis for breast cancer survivors and date of identification for women without breast 
cancer), menopausal status, previous use of hormone replacement therapy, smoking history, average lifetime alcohol intake, body mass index the 
year before reference date, income, education, and history of the following cardiovascular disease risk factors: diabetes, myocardial infarction, 
hypertension, dyslipidemia or stroke. Model for overall mortality included interaction between follow-up time and history of hypertension and 
myocardial infarction and models for CVD mortality included interaction between follow-up time and history of diabetes.
b
P-value for likelihood ratio test of interaction between breast cancer status and time.
cCause-specific hazard ratio estimates relative rate of CVD mortality between women with and without breast cancer, not accounting for 
competing causes of death.
dSubdistribution hazard ratio reflects association between breast cancer diagnosis and incidence of CVD death.
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Table 3
CVD mortality by treatment regimen for a population-based sample of breast cancer survivors and women 
without breast cancer. Long Island Breast Cancer Study Project, 1996-2009.
Cause-specific HRa,b (95% CI)
Treatment
Women without
Breast Cancer
Breast Cancer
Survivors without
Treatment
Breast Cancer
Survivors with
Treatment
Chemotherapy 1.0 1.1 (0.82, 1.6) 1.7 (1.1, 2.6)
Hormone Therapy 1.0 1.3 (0.82, 1.9) 1.3 (0.93, 1.8)
Radiation Therapy 1.0 1.5 (1.0, 2.2) 1.2 (0.82, 1.7)
Subdistribution HRa,c (95% CI)
Treatment
Women without
Breast Cancer
Breast Cancer
Survivors without
Treatment
Breast Cancer
Survivors with
Treatment
Chemotherapy 1.0 1.1 (0.77, 1.5) 1.4 (0.95, 2.2)
Hormone Therapy 1.0 1.2 (0.77, 1.8) 1.2 (0.86, 1.7)
Radiation Therapy 1.0 1.3 (0.89, 2.0) 1.1 (0.77, 1.6)
a
Models adjusted for age at reference date (date of diagnosis for breast cancer survivors and date of identification for women without breast 
cancer), menopausal status, previous use of hormone replacement therapy, smoking history, average lifetime alcohol intake, body mass index the 
year before reference date, income, education, and history of the following cardiovascular disease risk factors: diabetes, myocardial infarction, 
hypertension, dyslipidemia or stroke. Models also included interaction between follow-up time and history of diabetes.
bCause-specific hazard ratio estimates relative rate of CVD mortality between women with and without breast cancer, not accounting for 
competing causes of death.
cSubdistribution hazard ratio reflects association between breast cancer diagnosis and incidence of CVD death.
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